报道了一种新颖的钯催化脱羧级联环化反应,该反应通过使用α-氧代羧酸作为三碳插入单元来组装各种稠合的杂多环。该方案可通过使用不同的芳基碘化物(包括烯烃系的2-碘代苯甲酰胺和2-(2-碘代苯基)-)以中等到良好的产率合成异喹啉二酮和吲哚并[2,1 - a ]异喹啉酮稠合的苯并环庚酮1 H-吲哚。值得注意的是,该方法通过依次进行分子内碳氢合,CH活化和脱羧,实现了六元环和七元环的同时构建。
Die Anwendung des Bioisosterieprinzips auf den Arzneistoff Cyclandelat (Spasmocyclon®, Natil®) hatte zur Herstellung heteroanaloger Ester geführt; die pharmakologische Prüfung zweier Verbindungen, die wie Cyclandelat Diastereomerengemische waren, ergab einen schwachen calcium‐antagonistischen Effekt1).
Thiophenyl triazol-3-one derivatives as smooth muscle relaxants
申请人:——
公开号:US20030144333A1
公开(公告)日:2003-07-31
The present invention provides novel [1,2,4]triazole-3-one derivatives having the general formula (I)
1
wherein:
Q is
2
and R
1
, R
2
, R
3
, R
4
, R
5
and R
6
are as defined herein or a nontoxic pharmaceutically acceptable salt or solvate thereof which are smooth muscle relaxants and useful in treating disorders responsive to relaxation of smooth muscle such as asthma, irritable bowel syndrome, male erectile dysfunction and urinary incontinence.
Norbornene Derivatives-Controlled Palladium-Catalyzed Divergent Synthesis of Dibenzo[<i>a</i>,<i>c</i>]cycloheptenones and Fluorenones from Aryl Iodides and α-Oxocarboxylic Acids
作者:Liwei Zhou、Pengyang Jing、Zhiwei Li、Rui Liu、Jiannan Chen、Guobo Deng、Yun Liang、Yuan Yang
DOI:10.1021/acs.orglett.3c04065
日期:2024.1.26
A palladium-catalyzed divergent cascade decarboxylative annulation of aryliodides and α-oxocarboxylic acids using norbornene (NBE) derivatives as a controlled switch is reported. When NBE is used as a mediator, fluorenones are synthesized with moderate to excellent yields via a Catellani reaction that involves sequential ortho-C–H arylation and ipso-decarboxylative acylation of aryliodides. Employing
据报道,使用降冰片烯(NBE)衍生物作为受控开关,钯催化芳基碘化物和α-氧代羧酸的发散级联脱羧成环。当 NBE 用作介体时,通过 Catellani 反应以中等至优异的产率合成芴酮,该反应涉及芳基碘化物的连续邻位-C–H 芳基化和本身脱羧酰化。使用氧杂降冰片二烯 (ONBD) 代替 NBE 可以通过逆狄尔斯-阿尔德反应组装二苯并[ a , c ]环庚烯酮,而不是释放 ONBD。此外,该方法的合成效用通过产品的多样化得到证明。
UNTERHALT, BERNARD;GERES, PETER, ARCH. PHARM., 322,(1989) N1, C. 839-840